Skip to main content

Table 1 Profile of respondents to the questionnaire

From: Patient advocate perspectives on involvement in HTA: an international snapshot

Country Number of respondents Respondent type HTA agencies the respondents are involved with
Patient representative on HTA agency’s committee Member of a patient group [that potentially submits to an HTA agency]
United Kingdoma 2 -- 2 The National Institute for Health and Care Excellence (NICE); Scottish Medicines Consortium (SMC); All Wales Medicine Strategy Group (AWMSG); Various (rare diseases focus)
The Netherlands 1 -- 1 Zorginstituut Nederland (ZIN, The National Health Care Institute)
Canadaa 6 3 3 Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review (CDR); Pan-Canadian Oncology Drug Review (pCODR), Canadian Agency for Drugs and Technologies in Health (CADTH)
Australiaa 1 -- 1 Pharmaceutical Benefits Advisory Committee (PBAC); Medical Services Advisory Committee (MSAC)
Taiwan 2 -- 2 The National Health Insurance Administration (NHIA); Pharmaceutical Benefits and Reimbursement Scheme (PBRS)
Japan 1 -- 1 None
Italy 1 -- 1 None
Israel 1 -- 1 None
  1. aSome respondents indicated involvement with more than one agency